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We conducted a meta-analysis of randomized trials in which the effects of treatment with antidepressant medication were compared to the
effects of combined pharmacotherapy and psychotherapy in adults with a diagnosed depressive or anxiety disorder. A total of 52 studies
(with 3,623 patients) met inclusion criteria, 32 on depressive disorders and 21 on anxiety disorders (one on both depressive and anxiety dis-
orders). The overall difference between pharmacotherapy and combined treatment was Hedges’ g50.43 (95% CI: 0.31-0.56), indicating a
moderately large effect and clinically meaningful difference in favor of combined treatment, which corresponds to a number needed to treat
(NNT) of 4.20. There was sufficient evidence that combined treatment is superior for major depression, panic disorder, and obsessive-
compulsive disorder (OCD). The effects of combined treatment compared with placebo only were about twice as large as those of pharmaco-
therapy compared with placebo only, underscoring the clinical advantage of combined treatment. The results also suggest that the effects of
pharmacotherapy and those of psychotherapy are largely independent from each other, with both contributing about equally to the effects of
combined treatment. We conclude that combined treatment appears to be more effective than treatment with antidepressant medication
alone in major depression, panic disorder, and OCD. These effects remain strong and significant up to two years after treatment. Monother-
apy with psychotropic medication may not constitute optimal care for common mental disorders.
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Anxiety and depressive disorders are highly prevalent
(1,2) and are associated with a substantial loss of quality of
life for patients and their relatives (3,4), high levels of service
use, substantial economic costs (5-7), and a considerable
disease burden for public health (8). Effective treatments are
available for these disorders, including several types of psy-
chotherapy and antidepressant medication (9-11). Although
psychotherapy and antidepressants are about equally effec-
tive for most anxiety and depressive disorders (12), there is
some evidence that combined treatments may be more effec-
tive than each of these treatment alone (13-15). At the same
time, however, an increasing proportion of patients with
mental disorders in the past decade have received psycho-
tropic medication without psychotherapy (16,17). It is
important, therefore, to examine whether this has negative
effects on the quality of care.
We conducted a meta-analysis of studies comparing phar-
macotherapy alone with combined psychotherapy and phar-
macotherapy. Although some earlier meta-analyses have
examined this question, these were all aimed at one disorder,
especially depression (13-15) and panic (18,19). For some
other disorders – e.g., social anxiety disorder (SAD) and
obsessive-compulsive disorder (OCD) – several primary stud-
ies have been conducted, but these have not yet been inte-
grated into meta-analyses. The main goal of this paper,
therefore, is to provide an overall meta-analysis of studies
comparing antidepressant medication with combined treat-
ment for anxiety and depressive disorders. We also exam-
ined whether differences between combined treatment and
placebo only were larger than those between combined
treatment and pharmacotherapy, in order to determine the
relative contribution of psychotherapy and pharmacothera-
py to the effects of combined treatments.
METHODS
Identification and selection of studies
We used several strategies to identify relevant studies. We
searched four major bibliographical databases (PubMed,
PsycInfo, Embase and the Cochrane database of random-
ized trials). We first developed a search string for psycho-
therapy with text and key words indicating the different
types of psychotherapy and psychological treatments. This
search string was combined with search strings indicating
each of the disorders we included: major depression; dys-
thymia; generalized anxiety disorder (GAD); SAD; panic
disorder; OCD; post-traumatic stress disorder (PTSD). We
limited our search to randomized controlled trials. We also
checked the references of 116 earlier meta-analyses of psy-
chological treatments of the disorders (Figure 1).
We included randomized trials in which the effects of
treatment with antidepressant medication were compared
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to the effects of a combined antidepressant medication and
psychological treatment in adults with a depressive disor-
der, panic with or without agoraphobia, GAD, SAD, OCD
or PTSD. Only studies in which subjects met diagnostic cri-
teria for the disorder according to a diagnostic interview –
such as the Structured Clinical Interview for DSM-IV Axis I
Disorders (SCID-I), the Composite International Diagnos-
tic Interview (CIDI), or the Mini-International Neuro-
psychiatric Interview (MINI) – were included. Studies on
inpatients, adolescents and children (below 18 years of age)
were excluded. We also excluded maintenance studies,
aimed at people who had already recovered or partly recov-
ered after an earlier treatment. Studies in English, German,
Spanish, and Dutch were considered for inclusion.
Quality assessment and data extraction
We assessed the validity of included studies using the
“Risk of bias” assessment tool, developed by the Cochrane
Collaboration (20). This tool assesses possible sources of
bias in randomized trials, including the adequate generation
of allocation sequence; the concealment of allocation to
conditions; the prevention of knowledge of the allocated
intervention (masking of assessors); and dealing with incom-
plete outcome data (this was assessed as positive when
intention-to-treat analyses were conducted, meaning that all
randomized patients were included in the analyses). Assess-
ment of the validity of included studies was conducted by
Figure 1 Selection and inclusion of studies. GAD – generalized anxiety disorder, OCD – obsessive-compulsive disorder, PTSD – post-traumatic
stress disorder, SAD – social anxiety disorder
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two independent researchers, and disagreements were
solved through discussion.
We also coded participant characteristics (disorder; re-
cruitment method; target group); type of antidepressant
that was used (selective serotonin reuptake inhibitor, SSRI;
tricyclic antidepressant, TCA; serotonin-norepinephrine re-
uptake inhibitor, SNRI; monoamine oxidase inhibitor, MAOI;
other or manualized treatment including several antidepres-
sants); and characteristics of the psychotherapies (format;
number of sessions; and type of psychotherapy). The types
of psychotherapy we distinguished were cognitive behavior
therapy (CBT), interpersonal psychotherapy (IPT), and
others. Because most CBT therapies used a mix of different
techniques, we clustered them together in one large family of
CBT treatments. We rated a therapy as CBT when it included
cognitive restructuring or a behavioral approach (such as
exposure and response prevention). When a therapy used a
mix of CBT and IPT, we rated it as “other”, along with other
therapeutic approaches (such as psychodynamic therapies).
Meta-analyses
For each comparison between a pharmacotherapy and
the combined treatment group, the effect size indicating the
difference between the two groups at post-test was calculat-
ed (Hedges’ g). Effect sizes were calculated by subtracting
(at post-test) the average score of the pharmacotherapy
group from the average score of the combined treatment
group, and dividing the result by the pooled standard devia-
tion. Because some studies had relatively small sample sizes,
we corrected the effect size for small sample bias (21).
In the calculations of effect sizes in studies aimed at
patients with depressive disorders, we used only those
instruments that explicitly measured symptoms of depres-
sion. In studies examining anxiety disorders, we used only
instruments that explicitly measured symptoms of anxiety.
If more than one measure was used, the mean of the effect
sizes was calculated, so that each study provided only one
effect size. If means and standard deviations were not
reported, we used the procedures of the Comprehensive
Meta-Analysis software (version 2.2.021) to calculate the
effect size using dichotomous outcomes; and if these were
not available either, we used other statistics (such a t-value
or p-value). To calculate pooled mean effect sizes, we used
the above-mentioned software. Because we expected consid-
erable heterogeneity among the studies, we employed a ran-
dom effects pooling model.
Because the standardized mean difference (Hedges’ g) is
not easy to interpret from a clinical perspective, we trans-
formed these values into the number needed to treat (NNT),
using the formulae provided by Kraemer and Kupfer (22).
The NNT indicates the number of patients that have to be
treated in order to generate one additional positive outcome
(23).
We also calculated the relative risk (RR) of dropping out
from treatment in pharmacotherapy compared with com-
bined treatment. To compare the long-term effects of the
two treatments, we calculated the RR of having a positive
outcome at follow-up.
As a test of homogeneity of effect sizes, we calculated the
I2 statistic, which is an indicator of heterogeneity in percen-
tages. A value of 0% indicates no observed heterogeneity,
and larger values indicate increasing heterogeneity, with
25% as low, 50% as moderate, and 75% as high heterogene-
ity (24). We calculated 95% confidence intervals around I2
(25), using the non-central chi-squared-based approach
within the Heterogi module for Stata (26).
We conducted subgroup analyses according to the mixed
effects model, in which studies within subgroups are pooled
with the random effects model, while tests for significant dif-
ferences between subgroups are conducted with the fixed
effects model. For continuous variables, we used meta-
regression analyses to test whether there was a significant
relationship between the continuous variable and the effect
size, as indicated by a Z-value and an associated p-value.
We tested publication bias by inspecting the funnel plot
on primary outcome measures and by Duval and Tweedie’s
trim and fill procedure (27), which yields an estimate of the
effect size after the publication bias has been taken into
account. We also conducted Egger’s test of the intercept to
quantify the bias captured by the funnel plot and test whether
it was significant.
RESULTS
Selection and inclusion of studies
After examining a total of 21,729 abstracts (14,903 after
removal of duplicates), we retrieved 2,278 full-text papers
for further consideration. We excluded 2,226 of the
retrieved papers. The flow chart describing the inclusion
process, including the reasons for exclusion, is presented in
Figure 1. A total of 52 studies met inclusion criteria for this
meta-analysis (28-79). Selected characteristics of the includ-
ed studies are reported in Table 1.
Characteristics of included studies
In the 52 studies, 3,623 patients participated (1,767 in the
combined treatment conditions and 1,856 in the pharmaco-
therapy only conditions). Thirty-two studies were aimed at
depressive disorders (22 on major depression, including one
that was aimed at patients with both major depression and
OCD; 5 on dysthymia; and 5 on mixed mood disorders) and
21 at anxiety disorders (10 on panic disorder with or with-
out agoraphobia; 4 on OCD; 4 on SAD; 2 on PTSD, and
one on GAD). Most studies (n532) recruited patients
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Table 1 Selected characteristics of studies comparing treatment with antidepressant medication to combined treatment with psycho-
therapy and medication
Study Disorder Psychotherapy Medication Ncom Nmed Quality* Country
Azhar (28) PAN CBT SSRI 17 17 222 2 Other
Barlow et al (29) PAN CBT TCA 65 83 221 1 USA
Bellack et al (30) Mood Other TCA 17 18 221 2 USA
Bellino et al (31) MDD IPT SSRI 16 16 221 2 Europe
Berger et al (32) PAN Other SSRI 35 38 222 2 Europe
Blackburn et al (33) MDD CBT TCA 22 20 222 2 USA
Blanco et al (34) SAD CBT MAOI 32 35 111 1 USA
Blom et al (35) MDD IPT SNRI 33 30 221 1 Europe
Blomhoff et al (36) SAD BT SSRI 98 95 111 1 Europe
Browne et al (37) DYS IPT SSRI 122 117 111 2 Canada
Burnand et al (38) MDD DYN TCA 33 38 221 2 Europe
Crits-Christoph et al (39) GAD CBT SNRI 17 24 221 2 USA
Davidson et al (40) SAD CBT SSRI 42 39 111 1 USA
De Jonghe et al (41) MDD DYN Prot/Other 83 84 221 1 Europe
De Mello et al (42) DYS IPT MAOI 11 13 221 2 Other
Dozois et al (43) MDD CBT Prot/Other 21 21 212 2 Canada
Finkenzeller et al (44) MDD IPT SSRI 23 24 121 1 Europe
Foa et al (45) OCD BT TCA 19 27 221 2 USA
Hautzinger et al (46) Mood CBT TCA 32 24 221 1 Europe
Hellerstein et al (47) DYS Other SSRI 18 17 222 1 USA
Hollon et al (48) MDD CBT TCA 25 57 221 1 USA
Hsiao et al (49) MDD Other Prot/Other 24 26 121 1 Other
Keller et al (50) MDD Other SNRI 226 220 111 1 USA
King et al (51) PAN CBT Prot/Other 25 25 211 2 Other
Koszycki et al (52) PAN CBT SSRI 59 62 111 1 Canada
Lesperance et al (53) MDD IPT SSRI 67 75 111 1 Canada
Loerch et al (54) PAN CBT MAOI 14 16 221 1 Europe
Lynch et al (55) MDD Other Prot/Other 15 16 222 2 USA
Macaskill & Macaskill (56) MDD CBT TCA 9 9 222 2 Europe
Maina et al (57) MDD, OCD DYN SSRI 25 29 111 1 Europe
Markowitz et al (58) DYS IPT SSRI 21 24 111 1 USA
Misri et al (59) Mood CBT SSRI 19 16 121 1 Canada
Mitchell et al (60) Mood Other Prot/Other 45 53 111 1 USA
Murphy et al (61) MDD CBT TCA 22 24 112 1 USA
Mynors-Wallis et al (62) MDD PST SSRI 35 36 111 1 Europe
Naeem et al (63) MDD CBT SSRI 17 17 111 1 Other
Otto et al (64) PTSD CBT SSRI 5 5 222 2 USA
Prasko et al (65) SAD CBT MAOI 22 20 221 2 Europe
Ravindran et al (66) DYS CBT SSRI 24 22 111 2 Canada
Reynolds et al (67) MDD IPT TCA 16 25 221 1 USA
Rothbaum et al (68) PTSD BT SSRI 34 31 221 1 USA
Shamsaei et al (69) MDD CBT SSRI 40 40 121 2 Other
Shareh et al (70) OCD CBT SSRI 6 6 222 2 Other
Sharp et al (71) PAN CBT SSRI 29 29 222 2 Europe
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exclusively from clinical samples, and were aimed at adults
in general instead of a more specific population (such as
older adults or patients with a comorbid somatic disorder).
Most psychotherapies belonged to the family of cognitive
and behavioral therapies, while nine studies examined IPT,
and the remaining 10 examined other therapies (including
psychodynamic therapies). The number of treatment ses-
sions ranged from 5 to 56, with most therapies (n5 36) hav-
ing between 10 and 20 sessions. The antidepressants that
were examined in the studies included SSRIs (n5 22),
TCAs (n5 13), SNRIs (n5 3), MAOIs (n5 4), and treat-
ment protocols with different types of antidepressant medi-
cation (n5 10).
Most studies were conducted in the US (n5 20), or
Europe (n5 19). Two papers were published in German,
the rest in English.
Quality assessment
The quality of the studies varied (Table 1). Twenty-one
studies reported an adequate sequence generation, while
the other 31 did not. Nineteen studies reported allocation to
conditions by an independent (third) party. Thirty-nine
studies reported blinding of outcome assessors or used only
self-report outcomes, whereas 13 did not report blinding.
Thirty-one studies conducted intention-to-treat analyses (a
post-treatment score was analyzed for every patient even if
the last observation prior to attrition had to be carried
forward or that score was estimated from earlier response
trajectories). Thirteen studies met all four quality criteria,
another six studies met 3 criteria, while the remaining 33
studies met two criteria or less.
Effects of combined treatment versus antidepressants only
The overall mean effect size indicating the difference be-
tween pharmacotherapy only and combined treatment of
pharmacotherapy and psychotherapy at post-test for all 52
studies was 0.43 (95% CI: 0.31-0.56) in favor of the com-
bined treatment. This corresponds to a NNT of 4.20. Het-
erogeneity was moderate to high (I25 64; 95% CI: 52-73).
After exclusion of three possible outliers with extremely
large effect sizes (g>1.5; Table 2), the effect size was some-
what smaller (g5 0.37; 95% CI: 0.27-0.47; NNT5 4.85),
but heterogeneity was reduced to a moderate level (I25 48).
The results of these analyses are reported in Table 2. A forest
plot of the studies and their effect sizes is given in Figure 2.
For specific disorders, we found evidence that combined
treatment was more effective than pharmacotherapy alone in
major depression (g5 0.43; 95% CI: 0.29-0.57; NNT5 4.20),
panic disorder (g5 0.54; 95% CI: 0.25-0.82; NNT5 3.36),
and OCD (g50.70; 95% CI: 0.14-1.25; NNT52.63). We
also found some indication that combined treatment may be
more effective than pharmacotherapy in SAD (g50.32; 95%
CI: 20.01-0.71; NNT5 5.56), although this was not signifi-
cant (p<0.1). Insufficient evidence was found for dysthymia,
PTSD, and GAD.
Inspection of the funnel plot and Duval and Tweedie’s
trim and fill procedure pointed at some risk of publication
bias. After adjustment for possible publication bias, the
overall mean effect size was reduced from g50.43 (NNT
5 4.20) to g5 0.29 (95% CI: 0.15-0.43; NNT5 6.17; num-
ber of imputed studies: 10). Egger’s test of the intercept also
indicated significant publication bias (intercept: 1.33; 95%
CI: 0.24-2.42; p<0.01).
Table 1 Selected characteristics of studies comparing treatment with antidepressant medication to combined treatment with psycho-
therapy and medication (continued)
Study Disorder Psychotherapy Medication Ncom Nmed Quality* Country
Sirey et al (72) MDD Other Prot/Other 21 24 221 1 USA
Spinhoven et al (73) PAN CBT SSRI 20 19 222 1 Europe
Tenneij et al (74) OCD BT Prot/Other 34 46 221 1 Europe
Thompson et al (75) MDD CBT TCA 36 33 222 1 USA
van Apeldoorn et al (76) PAN CBT Prot/Other 36 37 111 1 Europe
Weissman et al (77) MDD IPT TCA 23 20 221 2 USA
Wiborg & Dahl (78) PAN DYN TCA 20 20 111 1 Europe
Wiles et al (79) Mood CBT Prot/Other 14 11 111 1 Europe
*A positive or negative sign is given for four quality criteria: allocation sequence, concealment of allocation to conditions, blinding of assessors, and intention-to-
treat analysis
BT – behavior therapy, CBT – cognitive behavior therapy, DYN – psychodynamic therapy, DYS – dysthymic disorder, GAD – generalized anxiety disorder, IPT – interper-
sonal psychotherapy, MAOI – monoamine oxidase inhibitor, MDD – major depressive disorder, Mood – mixed mood disorder, Ncom – number of patients in the com-
bined treatment condition, Nmed – number of patients in the pharmacotherapy condition, OCD – obsessive-compulsive disorder, PAN – panic disorder with or without
agoraphobia, Prot/Other – other antidepressant or protocolized treatment with antidepressants, PST – problem-solving therapy, PTSD – post-traumatic stress disorder,
SAD – social anxiety disorder, SNRI – serotonin-norepinephrine reuptake inhibitor, SSRI – selective serotonin reuptake inhibitor, TCA – tricyclic antidepressant
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We found no indication that combined treatment resulted
in lower dropout from treatment than pharmacotherapy
alone. The RR of dropping out of treatment, in the 35 studies
in which dropout was reported, was RR5 0.99 (95% CI:
0.95-1.03; I2524; 95% CI: 0-50).
Subgroup analyses indicated no significant differences
between the effects sizes of depressive and anxiety disorders,
between the different depressive disorders (while excluding
anxiety disorders), and between the different anxiety disor-
ders (while excluding depressive disorders) (Table 2). We also
found no indication that the effect sizes differed according to
the type of medication (SSRI; TCA; other or protocolized),
target group (adults in general or more specific target group),
psychotherapy treatment format (individual or group), type
of therapy (CBT; IPT; other), number of treatment sessions
(5-9; 10-12; 13-18;>19); and quality of the studies (meeting 3
or 4 criteria versus less than 3 criteria). We did find a trend
(p<0.1) indicating that the effect size may be higher in clinical
samples (g5 0.49) compared with samples that included
patients recruited from the community (g5 0.27).
We examined whether baseline severity was associated
with outcome in the 20 studies examining depressive disor-
ders. Mean baseline severity according to the Hamilton
Depression Rating Scale (HAM-D) was moderate in 16 of the
Table 2 Effects of combined therapy for adult depressive and anxiety disorders compared with antidepressant medication only
Ncomp g 95% CI I2 95% CI p NNT
Depressive and anxiety disorders 52 0.43 0.31-0.56 64 52-73 0.81 4.20
Possible outliers excluded (g> 1.5) 49 0.37 0.27-0.47 48 28-63 4.85
Depressive disorders 32 0.41 0.28-0.54 50 25-67 0.17 4.39
Major depression 23 0.43 0.29-0.57 30 0-58 4.20
Dysthymia 5 0.20 20.21-0.60 0 0-79 8.93
Mixed depressive disorders 5 0.56 0.12-0.99 73 32-89 3.25
Anxiety disorders 21 0.47 0.23-0.71 75 61-84 0.66 3.85
Panic disorder 10 0.54 0.25-0.82 82 68-90 3.36
OCD 4 0.70 0.14-1.25 67 5-89 2.63
SAD 4 0.32 20.01-0.71 65 0-88 5.56
PTSD 2 0.31 20.39-1.00 0 - 5.75
GAD 1 20.51 21.42-0.40 - - (3.55)
Subgroup analyses
Medication SSRI 22 0.34 0.15-0.53 76 63-84 0.45 5.26
TCA 13 0.46 0.22-0.71 9 0-47 3.91
Other/protocol 17 0.51 0.31-0.72 41 0-67 3.55
Recruitment Clinical samples 32 0.49 0.34-0.64 63 46-75 0.09 3.68
Community 16 0.28 0.08-0.47 45 2-70 6.41
Target group Adult in general 43 0.44 0.30-0.57 65 51-74 0.89 4.10
Specific group 9 0.41 0.12-0.71 64 27-83 4.39
Type of therapy CBT 33 0.51 0.35-0.66 70 58-79 0.20 3.55
IPT 9 0.24 20.05-0.53 32 0-69 7.46
Other 10 0.37 0.09-0.64 10 0-50 4.85
Number of sessions 5-9 11 0.67 0.40-0.93 86 76-91 0.10 2.75
10-12 16 0.24 0.03-0.46 48 8-71 7.46
13-18 18 0.47 0.26-0.67 4 0-52 3.85
>19 7 0.41 0.06-0.76 33 0-72 4.39
Treatment format Individual 42 0.46 0.32-0.59 68 55-76 0.35 3.91
Group 9 0.29 20.02-0.60 40 0-73 6.17
Quality score <3 32 0.49 0.33-0.66 62 44-74 0.23 3.68
3 or 4 20 0.35 0.16-0.54 67 47-79 5.10
CBT – cognitive behavior therapy, GAD – generalized anxiety disorder, IPT – interpersonal psychotherapy, Ncomp – number of comparisons, NNT – number
needed to treat, OCD – obsessive-compulsive disorder, PTSD – post-traumatic stress disorder, SAD – social anxiety disorder, SNRI – serotonin-norepinephrine
reuptake inhibitor, SSRI – selective serotonin reuptake inhibitor, TCA – tricyclic antidepressant
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20 studies (score 18-24), severe in three studies (score >24),
and mild in one study (score <18) (80). In a meta-regression
analysis, we did not find any indication that the effect size of
difference between pharmacotherapy and combined treat-
ment was associated with baseline severity of depression
(slope: 0.007; 95% CI:20.022-0.038; p50.63).
Combined treatment versus placebo
In 11 of the 53 studies, the combined treatment could be
compared to a pill placebo control group. All of these studies
also included a psychotherapy-only condition (with or without
a pill placebo), as well as a pharmacotherapy-only condition.
This allowed us to calculate the effect sizes indicating the
Table 3 Direct comparisons between psychotherapy, pharmaco-
therapy, combined psychotherapy and pharmacotherapy, and
placebo in anxiety and depressive disorders (Hedges’ g)
Ncomp g 95% CI I2 95% CI NNT
Combined vs. placebo 11 0.74 0.48-1.01 65 33-82 2.50
Pharmacotherapy vs.
combined
11 0.37 0.12-0.63 43 0-72 4.85
Pharmacotherapy vs.
placebo
11 0.35 0.21-0.49 0 0-60 5.10
Psychotherapy vs.
combined
11 0.38 0.16-0.59 53 8-76 4.72
Psychotherapy vs.
placebo
11 0.37 0.11-0.64 68 41-83 4.85
Ncomp - number of comparisons, NNT – number needed to treat
Figure 2 Effects of pharmacotherapy compared to combined treatment with pharmacotherapy and psychotherapy (Hedges’ g)
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difference between pharmacotherapy and placebo, psycho-
therapy (with or without a pill placebo) and placebo, as well
as between combined treatment and placebo. With these
effect sizes we could estimate the contribution of pharmaco-
therapy and psychotherapy to the effects of combined
treatment.
The results of the analyses are presented in Table 3. The
effects of combined treatment compared with placebo are
large (g5 0.74; 95% CI: 0.48-1.01; NNT5 2.50), with mod-
erate to high heterogeneity (I25 65; 95% CI: 33-82). In
these 11 studies, the effect size of pharmacotherapy com-
pared with placebo was g5 0.35 (95% CI:0.21-0.49) and
Table 4 Long-term follow-up effects in included studies: definitions of positive outcome and relative risk associated with each
outcome
Study Outcome Follow-up (months) RR 95% CI
Barlow et al (29) CGI response 6-8 1.52 1.07-2.16
Barlow et al (29) CGI response 9-12 1.39 0.75-2.58
Barlow et al (29) PDSS response 6-8 1.52 1.07-2.16
Barlow et al (29) PDSS response 9-12 1.31 0.69-2.45
Bellack et al (30) <10 on BDI1HAMD 6-8 1.30 0.53-3.16
Blanco et al (34) remission 3-5 2.07 1.08-3.96
Blanco et al (34) response 3-5 1.61 1.09-2.37
Hautzinger et al (46) response 9-12 1.91 1.07-3.39
Hellerstein et al (47) remission 3-5 0.62 0.23-1.66
Hellerstein et al (47) response 3-5 1.53 0.74-3.14
Hollon et al (48) no relapse 9-12 1.87 0.99-3.52
Hollon et al (48) no relapse 13-24 1.73 0.90-3.32
Keller et al (50) no relapse 3-5 1.01 0.95-1.08
Loerch et al (54) FQ<10 6-8 1.17 0.79-1.74
Loerch et al (54) FQ>50% improvement 6-8 1.17 0.79-1.74
Lynch et al (55) BDI<9 6-8 1.29 0.43-3.88
Lynch et al (55) HAMD<7 6-8 2.35 1.07-5.16
Maina et al (57) CGI success 6-8 1.55 0.62-3.86
Maina et al (57) HAMD response 6-8 1.16 0.47-2.86
Maina et al (57) YBOCS response 6-8 0.77 0.38-1.58
Mitchell et al (60) HAMD<9 3-5 2.08 1.13-3.82
Mitchell et al (60) HAMD<9 9-12 1.76 1.01-3.08
Mitchell et al (60) HAMD<9 13-24 1.42 0.91-2.23
Murphy et al (61) no relapse 9-12 1.71 0.61-4.80
Mynors-Wallis et al (62) recovered 9-12 1.18 0.81-1.73
Prasko et al (65) no relapse 3-5 1.62 0.89-2.95
Prasko et al (65) no relapse 9-12 2.16 0.81-5.77
Prasko et al (65) no relapse 13-24 1.94 0.71-5.31
Reynolds et al (67) no relapse 3-5 9.58 2.09-43.94
Sharp et al (71) FQ-AG: clinically significant change 6-8 1.60 0.88-2.91
Sharp et al (71) HAMA: clinically significant change 6-8 1.64 0.95-2.82
Sharp et al (71) SRT: clinically significant change 6-8 2.50 0.88-7.07
van Apeldoorn et al (76) remission 6-8 1.48 0.63-3.47
van Apeldoorn et al (76) remission 9-12 1.93 0.87-4.27
Wiborg & Dahl (78) no DSM relapse 9-12 3.20 1.45-7.05
Wiborg & Dahl (78) remission 9-12 3.20 1.45-7.05
BDI – Beck Depression Inventory, CGI – Clinical Global Impression, FQ – Fear Questionnaire, FQ-AG – Fear Questionnaire, Agoraphobia Subscale, HAMA –
Hamilton Anxiety Rating Scale, HAMD – Hamilton Depression Rating Scale, PDSS – Postpartum Depression Screening Scale, RR – relative risk, SRT – Kellner
and Sheffield Symptom Rating Scale, YBOCS – Yale-Brown Obsessive Compulsive Scale
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that of psychotherapy compared with placebo was g50.37
(95% CI: 0.11-0.64). This suggests that the effects of psycho-
therapy and those of pharmacotherapy are largely indepen-
dent of each other, and each add about 50% to the overall
effects of combined treatment. The independence of the
effects of the two kinds of treatments is further supported by
the effect sizes of pharmacotherapy versus combined treat-
ment (g50.37 in this sample), and those of psychotherapy
versus combined treatment (g5 0.38).
Long-term differences between pharmacotherapy and
combined treatment
Long-term differences between pharmacotherapy and
combined treatment were reported in 19 studies, with
follow-up periods varying from 3 to 24 months. Because the
way positive outcomes were defined differed from study to
study, we have reported the definition of a positive outcome
at each of the follow-up points in Table 4.
The RR of having a positive outcome for all follow-up
periods together was 1.48 (95% CI: 1.23-1.78; NNT5 4.29),
and ranged from RR5 1.40 to 1.51 (NNTs: 3.41 to 6.90) for
the four follow-up periods we distinguished. In each of the
four follow-up periods, combined treatment was significant-
ly more effective than pharmacotherapy alone (Table 5).
DISCUSSION
In this meta-analysis, we found clear evidence that com-
bined treatment with psychotherapy and antidepressant
medication is more effective than treatment with antide-
pressant medication alone. This difference was significant
for major depression, panic disorder, and OCD. A trend
indicated possible superior effects in SAD. We did not find
sufficient evidence for a significant difference in dysthymia,
PTSD and GAD, but this could be due to the small number
of studies and associated lack of statistical power for these
disorders. The superior effects of combined treatment
remained significant at one to two-year follow-up.
We found that the superior effects of combined treatment
may have been overestimated by publication bias, which is
in line with earlier research on pharmacotherapy (81) as
well as psychotherapy (82), showing evidence of publication
bias in both fields. However, even after adjusting for publi-
cation bias, the superiority of combined treatment was still
statistically significant.
We also found some indications that the difference be-
tween pharmacotherapy and combined treatment was espe-
cially high in clinical samples compared with samples that
were (in part) recruited from the community. Although this
difference was only marginally significant (p<0.1), it does
suggest that patients actively seeking treatment may benefit
more from combined treatment than people who are re-
cruited from the community.
Research up to now has not been able to answer the ques-
tion of how large the effects of combined treatment are com-
pared with pill placebo only. We found indications that the
effects of combined treatment compared with placebo only
were about twice as large as those of pharmacotherapy com-
pared with placebo only.
Until now it has not been established well whether the
effects of pharmacotherapy and those of psychotherapy are
complementary to each other, whether they have effects
independent from each other, or whether combined treat-
ments lead to higher effects than the sum of the two treat-
ments alone (83,84). The present study indicates that the
effects of psychotherapy and pharmacotherapy may be
largely independent from each other and additive, not inter-
fering with each other, and both contribute about equally to
the effects of combined treatment.
From a clinical point of view, this paper suggests that
combined treatment should be used in more patients than is
currently done in clinical practice. Most patients receive
either pharmacotherapy or psychotherapy (16,17), and only
a minority receives combined therapy. Combined treatment
is especially given to more severe and chronic cases. Our
data suggest that the superior effects of combined treatment
are not associated with baseline severity, at least in depres-
sion. Because the effects of the two treatments seem to be
largely independent from each other, combined treatment
may also be beneficial in less severe cases.
This study has some limitations. First, it is not possible to
blind comparisons of pharmacotherapy to combined treat-
ment and this may have introduced a bias in the outcomes.
Second, because patients refusing antidepressants may not
have been willing to be enrolled in trials, there may have been
a sampling bias that could limit the generalizability of these
findings. Third, we found considerable levels of heterogeneity
among the studies, which could not fully be explained by
moderator analyses. Another limitation was the relatively
small number of included studies for some disorders. A
final limitation is that we considered psychotherapy and
Table 5 Long-term effects of combined therapy for anxiety and
depressive disorders compared with antidepressive medication
only: relative risk of having a positive outcome
Ncomp RR 95% CI I2 95% CI NNT
3-5 months after end
of treatment
6 1.60 1.03-2.48 75 43-89 3.41
6-8 months after end
of treatment
7 1.40 1.13-1.73 0 0-71 6.90
9-12 months after end
of treatment
10 1.51 1.25-1.84 13 0-56 4.52
13-24 months after end
of treatment
4 1.49 1.12-1.98 0 0-85 4.35
All long-term outcomes
pooled
19 1.48 1.23-1.78 55 25-73 4.29
Ncomp – number of comparisons, NNT – Number needed to treat, RR – rela-
tive risk
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pharmacotherapy as monolithic treatments, while in fact sev-
eral different treatments were used in the included studies.
In sum, the present study found superior effects of com-
bined treatment over pharmacotherapy alone, which are
significant and relevant up to two years after treatment.
These results thus support the use of combined treatment
for common mental disorders rather than monotherapy
with psychotropic medication without psychotherapy.
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